Summary of COVID-19 medicines guidance: Policy, Commissioning and Managerial

This page summarises and signposts to medicine related guidance we’re aware of from professional and government bodies relating to Policy and Commissioning during coronavirus pandemic.

Our advice is constantly reviewed as the pandemic situation evolves.

Whilst we have tried to ensure that the information on this page is complete, please report a concern if you feel anything is omitted or inaccurate.

To see our professional guidance summaries for other clinical areas, click here

Advice in this area includes:

NHS England/NHS Improvement: Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and over) version 2 

Last updated 6 November 2020

  • This policy sets out the interim clinical commissioning position for the use of remdesivir for patients with COVID-19.

 

NHS England/NHS Improvement: Clinical management of persons admitted to hospital with suspected COVID-19 infection

Last updated 19 March 2020

  • This generalised guidance is for clinicians caring for adults and children admitted to hospital with suspected COVID-19 infection.
  • It describes the categorisation of types of clinical syndromes associated with COVID-19 infection
  • Early supportive therapy and monitoring including the need for oxygen supplementation, the use of empirical antibiotic treatment, use of corticosteroids and use of non-invasive ventilation is discussed.
  • Management of hypoxaemic respiratory failure, Acute Respiratory Distress Syndrome (ARDS), and septic shock is included.
  • General Guidance is also given on the management of pregnant patients.

 

NHS England/NHS Improvement: Clinical guide for the management of remote consultations and remote working in secondary care during the coronavirus pandemic

Last updated 27 March 2020

  • This guidance for clinicians and managers outlines practical information about delivering remote consultations and other ways of remote working in secondary care
  • It includes detailed guidance on how to conduct the consultation itself, and exception criteria.

 

HM Government: COVID-19: guidance for health professionals

Last updated 20 October 2020

  • This is a repository of a number of guidelines regarding the assessment and management of suspected and confirmed UK cases.
  • It includes general guidance as well as guidance on infection prevention and control, adult social care, sampling and laboratory diagnostics, and surveillance reports.
  • COVID-19 risk pathways are included to support returning services.

 

HM Government: Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19

Last updated 05 November 2020

  • This guidance defines those people who are classed as clinically extremely vulnerable, including young people.
  • It is written for these patient groups, their family, friends and carers and is available in a number of translations.
  • It provides a definition of shielding and other ways to minimise risk
  • Guidance has been updated to be in-line with national lockdown restrictions commencing 5 November 2020.

 

NHS England/NHS Improvement: Community pharmacy in the context of coronavirus (COVID-19)

Last updated 26 October 2020

  • This is a Standard Operating Procedure which applies to community pharmacies operating under contract to the NHS in England.
  • It sets out general principles for the delivery of services during the COVID-19 pandemic.
  • The SOP covers a wide range of principles and includes guidance on maintaining access to community pharmacy services, managing outbreaks, providing information and support for patients and the public, and information on the expanded seasonal influenza programme.

 

HM Government: Medicines and Healthcare products Regulatory Agency (MHRA) Coronavirus Yellow Card reporting site 

Last updated 21 August 2020

Summary

  • Healthcare professionals, patients and carers can report all suspected adverse drug reactions associated with any medicines used in patients with confirmed or suspected COVID-19.
  • This includes medicines to manage long term or pre-existing conditions and medicines being used off-label and in clinical trials.
  • The site has been developed as part of the MHRA’s work to protect the public through enhanced COVID-19 vigilance and in preparation for large-scale use of potential new or repurposed medicines, medical devices, diagnostic tests and future vaccines.
  • Reporting for incidents in clinical trials should also still be reported in line with trial protocols.

 

Administration update  (10 November 2020): editorial amendments only.